Registration of Clinical Trials for Investigational Medicinal Products and Publication of Summary Results from 1 January 2021

You should continue to use existing and established international registers such as ISRCTN registry, or For trials involving both the UK and the EU sites, a record in the EU Clinical Trials Register will exist.  Registration should occur before the first participant is recruited and no later than six weeks after recruitment of the first participant.

You should publish your summary results within these timeframes in the public register (or registers) where you have registered your clinical trial. You do not need to submit this clinical trial summary report to the MHRA as well. If your clinical trial is not on a public register, summary results should be submitted to the MHRA.

Source: MHRA guideline on  Registration of clinical trials for investigational medicinal products and publication of summary results from 1 January 2021


  • Blogs

    Brexit: The MHRA and The Proposed eSubmission Portal

    Read More
  • White Papers

    Impact of COIVD – 19 on FMCG Supply Chain Regulatory Compliance

    Read More
  • Case Studies

    Expedited Product Classification and NIOSH Certification for N95 Respirator

    Read More

What our Clients Say?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Quick Inquiry